{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:39:16Z","timestamp":1790699956770,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008978","name":"Health and Family Planning Commission of Heilongjiang Province","doi-asserted-by":"publisher","award":["2017-036"],"award-info":[{"award-number":["2017-036"]}],"id":[{"id":"10.13039\/501100008978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000855","name":"University of Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["H2501"],"award-info":[{"award-number":["H2501"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.amjmed.2020.03.019","type":"journal-article","created":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T01:22:49Z","timestamp":1586654569000},"page":"1195-1202.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7626-7751","authenticated-orcid":false,"given":"Yutao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amjmed.2020.03.019_bib0001","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"issue":"7","key":"10.1016\/j.amjmed.2020.03.019_bib0002","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"issue":"9921","key":"10.1016\/j.amjmed.2020.03.019_bib0003","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.amjmed.2020.03.019_bib0004","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.amjmed.2020.03.019_bib0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.amjmed.2020.03.019_bib0006","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"Borre","year":"2018","journal-title":"Thromb Haemost"},{"issue":"7","key":"10.1016\/j.amjmed.2020.03.019_bib0007","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.amjcard.2017.06.058","article-title":"Bleeding risk scores in atrial fibrillation and venous thromboembolism","volume":"120","author":"Zulkifly","year":"2017","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2020.03.019_bib0008","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jth.14692","article-title":"Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a network meta-analysis","volume":"18","author":"Chang","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.amjmed.2020.03.019_bib0009","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.amjmed.2017.09.009","article-title":"Comparing bleeding risk assessment focused on modifiable risk factors only versus validated bleeding risk scores in atrial fibrillation","volume":"131","author":"Guo","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2020.03.019_bib0010","doi-asserted-by":"crossref","first-page":"31755","DOI":"10.1038\/srep31755","article-title":"Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: the Beijing PLA Hospital Atrial Fibrillation Project","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.amjmed.2020.03.019_bib0011","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-0038-1636534","article-title":"Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors","volume":"118","author":"Chao","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2020.03.019_bib0012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2017.11.025","article-title":"Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study","volume":"254","author":"Chao","year":"2018","journal-title":"Int J Cardiol"},{"issue":"12","key":"10.1016\/j.amjmed.2020.03.019_bib0013","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1160\/TH17-10-0710","article-title":"Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED Score. The AMADEUS Trial","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.amjmed.2020.03.019_bib0014","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.amjmed.2020.03.019_bib0015","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s12471-019-01331-x","article-title":"First report of a comparative patient-oriented perspective on the use of non-vitamin-K oral anticoagulants or vitamin-K antagonists in atrial fibrillation: patients' experiences, side-effects and practical problems leading to non-adherence","volume":"27","author":"Bennaghmouch","year":"2019","journal-title":"Neth Heart J"},{"issue":"11","key":"10.1016\/j.amjmed.2020.03.019_bib0016","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.3390\/jcm8111919","article-title":"Impact of a prescription support tool to improve adherence to the guidelines for the prescription of oral antithrombotics: the Combi-AT randomized controlled trial using clinical vignettes","volume":"8","author":"Zerah","year":"2019","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.amjmed.2020.03.019_bib0017","doi-asserted-by":"crossref","first-page":"e13077","DOI":"10.2196\/13077","article-title":"Digital competencies and attitudes toward digital adherence solutions among elderly patients treated with novel anticoagulants: qualitative study","volume":"22","author":"Herrmann","year":"2020","journal-title":"J Med Internet Res"},{"issue":"12","key":"10.1016\/j.amjmed.2020.03.019_bib0018","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.amjmed.2017.07.003","article-title":"Mobile health technology for atrial fibrillation management integrating decision support, education, and patient involvement: mAF App Trial","volume":"130","author":"Guo","year":"2017","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2020.03.019_bib0019","doi-asserted-by":"crossref","first-page":"e13352","DOI":"10.1111\/ijcp.13352","article-title":"Mobile Health (mHealth) technology for improved screening, patient involvement and optimising integrated care in atrial fibrillation: the mAFA (mAF-App) II randomised trial","volume":"73","author":"Guo","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"13","key":"10.1016\/j.amjmed.2020.03.019_bib0020","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.jacc.2020.01.052","article-title":"Mobile Health to improve optimization of integrated care in patients with atrial fibrillation: mAFA-II trial","volume":"75","author":"Guo","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.amjmed.2020.03.019_bib0021","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrcardio.2017.153","article-title":"The ABC pathway: an integrated approach to improve AF management","volume":"14","author":"Lip","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.amjmed.2020.03.019_bib0022","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.amjmed.2020.03.019_bib0023","first-page":"611","article-title":"Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process","volume":"35","author":"Chang","year":"2019","journal-title":"Can J Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2020.03.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104584","article-title":"Clinical risk factors of thromboembolic and major bleeding events for patients with atrial fibrillation treated with rivaroxaban in Japan","volume":"29","author":"Miyamoto","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.amjmed.2020.03.019_bib0025","article-title":"Management of patients with newly-diagnosed atrial fibrillation: insights from the BALKAN-AF survey","volume":"26","author":"Kozie\u0142","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"10.1016\/j.amjmed.2020.03.019_bib0026","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3389\/fphar.2018.01353","article-title":"Estimating adherence based on prescription or dispensation information: impact on thresholds and outcomes. A real-world study with atrial fibrillation patients treated with oral anticoagulants in Spain","volume":"9","author":"Hurtado-Navarro","year":"2018","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.amjmed.2020.03.019_bib0027","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/europace\/euz273","article-title":"The optimal drug adherence to maximize the efficacy and safety of non-vitamin K antagonist oral anticoagulant in real-world atrial fibrillation patients","volume":"22","author":"Kim","year":"2020","journal-title":"Europace"},{"issue":"7","key":"10.1016\/j.amjmed.2020.03.019_bib0028","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1080\/03007995.2018.1428543","article-title":"Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants","volume":"34","author":"Deshpande","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.amjmed.2020.03.019_bib0029","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2019-315307","article-title":"Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study","volume":"106","author":"Banerjee","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2020.03.019_bib0030","first-page":"e13483","article-title":"Minor bleeding affects the level of knowledge in patients with atrial fibrillation on oral anticoagulant therapy","author":"Metzgier-Gumiela","year":"2020","journal-title":"Int J Clin Pract"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320302746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320302746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:21:50Z","timestamp":1757582510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934320302746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0002934320302746"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.03.019","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regular Bleeding Risk Assessment Associated with Reduction in Bleeding Outcomes: The mAFA-II Randomized Trial","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}